News | Patient Monitors | March 30, 2017

Acarix CADScor System Rules Out Coronary Artery Disease With 97 Percent Negative Predictive Value

Handheld system combines acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms to produce a patient-specific CAD score in less than 10 minutes

Acarix, CADScor System, coronary artery disease detection, clinical study, ACC.17

March 30, 2017 — Acarix AB recently announced the results from a new multi-center trial of its handheld CADScor System for non-invasive, non-radiation acoustic detection of coronary artery disease (CAD). The results were presented at the American College of Cardiology (ACC) 2017 Annual Scientific Meeting, held March 17-19 in Washington, D.C., and showed the handheld CADScor System rules out CAD with 97 percent negative predictive value. The results confirm the company’s previously announced figures which, prior to this study, were unconfirmed.

The trial involved 1,675 patients from two Danish hospitals with a low to intermediate likelihood of CAD referred for cardiac computed tomography angiography (CTA) and showed that the handheld CADScor System rules out CAD with 97 percent negative predictive value. Acarix believes this opens the possibility of use as a frontline test, reducing patient anxiety and waiting times, as well as improving triage for patients needing more expensive and invasive diagnostic modalities.

The system combines acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a handheld device to provide a patient-specific CAD score in less than 10 minutes. The research was led by Principal Investigator Morten Böttcher, M.D., Ph.D., FESC, and by Simon Winther, M.D., Ph.D., Department of Cardiology, Aarhus University Hospital, Denmark. “Despite the availability of improved risk stratification algorithms, the incidence of normal investigations such as nuclear or CT imaging remains high. We therefore tested the diagnostic accuracy of the CADScor System for ruling out CAD to see if it could be used to reduce demand for more advanced diagnostic modalities. We have concluded that, with its ability to rule out CAD with a 97 percent negative predictive value, this advanced, easy to use, stethoscope like device could indeed be deployed as a frontline test,” they said.

A CAD-score was recorded in all 1,675 patients enrolled in the trial, with the CAD-score algorithm including both acoustic features and clinical risk factors (gender, age and hypertension). Low risk was indicated by a CAD-score value less or equal to 20. The algorithm CAD-score version 3 was developed using recordings from 711 patients from previous studies and a training cohort of 589 patients from the present study. The remaining 1,086 patients were used as the validation cohort. The CAD-score was successfully analyzed in 1,464 patients (87 percent). Hemodynamic-significant CAD was present in 134 patients (9.3 percent). There were no differences in the performance of the CAD-score algorithm in the training vs. validation cohorts. In the entire cohort, the CAD-score differed between coronary artery calcium score (CACS) groups CACS=0 (n=745), CACS 1-400 (n=550) and CACS more than 400 (n=142); CAD-score: 17 ±11, 24 ±12, and 30 ±12 (p less than 0.001). CAD-score was also significantly lower for patients without vs. with hemodynamic-significant stenosis 20 ±12 vs 30 ±12 (p less than 0.001). Diagnostic performance evaluated by receiver operating characteristic curve showed an accuracy of: 72 percent (CI: 67-77 percent). CAD-score cut-off less or equal to 20 had an accuracy of:

  • Sensitivity: 81 percent (CI: 74-88 percent);
  • Specificity: 53 percent (CI: 50-56 percent);
  • PPV: 15 percent (CI: 13-18 percent); and
  • NPV: 97 percent (CI: 95-98 percent).

For more information: www.acarix.com

Related Content

Feature | ACC | By Melinda Taschetta-Millane

In April, the cardiology community converged face-to-face in Orlando for The American College of Cardiology’s (ACC22) ...

Home May 11, 2022
Home
News | ACC

April 12, 2022 – The American College of Cardiology (ACC) is establishing a new award in honor of Valentin Fuster, MD ...

Home April 12, 2022
Home
News | ACC
April 4, 2022 – Esperion presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL) ...
Home April 04, 2022
Home
News | ACC

April 3, 2022 — egnite, Inc., an advanced technology digital health company focused on providing artificial intelligence ...

Home April 03, 2022
Home
News | ACC

April 3, 2022 — A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath ...

Home April 03, 2022
Home
News | ACC

April 1, 2022 — Royal Philips, a global leader in health technology, announced new additions to its innovative ...

Home April 01, 2022
Home
News | ACC
March 31, 2022 – Healthcare AI solutions provider Aidoc will be delivering a live demonstration of its comprehensive AI ...
Home March 31, 2022
Home
News | ACC
March 31, 2022 – Experts from the Smidt Heart Institute at Cedars-Sinai, home to California’s top-ranked cardiology and ...
Home March 31, 2022
Home
News | ACC
March 31, 2022 – CathWorks has announced that the results of its most recent outcomes study on the CathWorks FFRangio ...
Home March 31, 2022
Home
News | ACC
February 15, 2022 — The American College of Cardiology’s Cardiovascular Summit Virtual (CV Summit) will feature three ...
Home February 15, 2022
Home
Subscribe Now